We are live on
!
Find out more
Adage Capital Partners Portfolio holdings
AUM
$64.8B
1-Year Est. Return
42.7%
This Fund
S&P 500
This Quarter
Est. Return
-12.58%
1 Year Est. Return
+42.7%
3 Year Est. Return
+139.29%
5 Year Est. Return
+204.38%
10 Year Est. Return
+829.83%
AUM
$43.6B
AUM Growth
-$9.03B
(-17%)
Cap. Flow
-$1.48B
Cap. Flow
% of AUM
-3.4%
Top 10 Holdings %
Top 10 Hldgs %
21.41%
Holding
1,190
New
110
Increased
278
Reduced
409
Closed
115
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
+$364M |
| 2 |
SIVB
SVB Financial Group
SIVB
|
+$155M |
| 3 |
Textron
TXT
|
+$103M |
| 4 |
TWTR
Twitter, Inc.
TWTR
|
+$102M |
| 5 |
Sanofi
SNY
|
+$96.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Royalty Pharma
RPRX
|
+$333M |
| 2 |
ExxonMobil
XOM
|
+$242M |
| 3 |
Dollar Tree
DLTR
|
+$231M |
| 4 |
Nutrien
NTR
|
+$213M |
| 5 |
National Vision
EYE
|
+$198M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 22.53% |
| 2 | Healthcare | 17.73% |
| 3 | Financials | 14.85% |
| 4 | Consumer Discretionary | 9.35% |
| 5 | Industrials | 8.07% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
126
Intuitive Surgical
ISRG
$127B
| $75M | 0.17% |
373,883
-49,700
| -12% | -$11.7M |
|
127
General Dynamics
GD
$104B
| $72.1M | 0.17% |
325,853
-208,535
| -39% | -$48M |
|
128
Progressive
PGR
$123B
| $72M | 0.17% |
619,085
+8,800
| +1% | +$998K |
|
129
NCR Voyix
VYX
$1.14B
| $72M | 0.17% |
3,770,648
+196,412
| +5% | +$4.19M |
|
130
CSX Corp
CSX
$93.4B
| $71.9M | 0.16% |
2,474,404
-51,700
| -2% | -$1.69M |
|
131
Blackrock
BLK
$169B
| $71.9M | 0.16% |
117,980
-3,600
| -3% | -$2.34M |
|
132
Jabil
JBL
$33B
| $68.9M | 0.16% |
1,344,619
+581,952
| +76% | +$33.7M |
|
|
TXNM
133
TXNM Energy Inc
TXNM
$6.41B
| $68.5M | 0.16% |
1,433,949
+483,949
| +51% | +$22.7M |
|
134
Exelon
EXC
$47.2B
| $68M | 0.16% |
1,499,957
-1,027,000
| -41% | -$48.3M |
|
135
Dominion Energy
D
$60.8B
| $67.4M | 0.15% |
844,911
-900
| -0.1% | -$74.3K |
|
136
Gilead Sciences
GILD
$162B
| $67.4M | 0.15% |
1,090,277
+898,300
| +468% | +$55.6M |
|
|
NVMI
137
Nova
NVMI
$12.4B
| $66.9M | 0.15% |
756,235
+117,798
| +18% | +$11.7M |
|
138
Applied Materials
AMAT
$403B
| $66.7M | 0.15% |
732,801
+30,200
| +4% | +$3.31M |
|
139
TJX Companies
TJX
$174B
| $66.4M | 0.15% |
1,188,148
-57,500
| -5% | -$3.48M |
|
140
Legend Biotech
LEGN
$3.59B
| $66M | 0.15% |
1,200,000
+390,000
| +48% | +$16.5M |
|
141
RTX Corp
RTX
$290B
| $65.7M | 0.15% |
683,286
+245,912
| +56% | +$23.6M |
|
142
F5
FFIV
$22.9B
| $63.7M | 0.15% |
416,500
+71,600
| +21% | +$12.5M |
|
|
MRSH
143
Marsh
MRSH
$90.5B
| $63.3M | 0.15% |
407,761
-444,500
| -52% | -$71.2M |
|
144
L3Harris
LHX
$51.6B
| $63M | 0.14% |
260,859
+162,636
| +166% | +$39.3M |
|
145
Monster Beverage
MNST
$94.3B
| $62.8M | 0.14% |
1,354,564
-180,200
| -12% | -$7.84M |
|
146
Howmet Aerospace
HWM
$113B
| $62.6M | 0.14% |
1,989,127
-1,983,694
| -50% | -$67.9M |
|
147
Equinix
EQIX
$101B
| $62.3M | 0.14% |
94,768
+700
| +0.7% | +$485K |
|
148
Humana
HUM
$43.7B
| $61.6M | 0.14% |
131,710
-2,500
| -2% | -$1.11M |
|
149
Estee Lauder
EL
$30.4B
| $61.5M | 0.14% |
+241,384
| New | +$61.2M |
|
|
EXE
150
Expand Energy Corp
EXE
$21.8B
| $61.3M | 0.14% |
755,812
+422,258
| +127% | +$38.1M |
|
Similar funds
Adage Capital Partners's Q2 2022 Portfolio in Review
As of Q2 2022, Adage Capital Partners held 1,190 positions worth $43.6B, down 17% from $52.7B the previous quarter. Its ten largest holdings account for 21% of the portfolio.
Adage Capital Partners withdrew a net $1.48B in Q2 2022, closing 115 positions and reducing 409 holdings. Its most notable exit was Nutrien, an estimated $213M position sold in full.
By sector, the portfolio is most concentrated in Technology at 23% of assets, down from 23% a quarter earlier, followed by Healthcare and Financials.
Against the trend, Adage Capital Partners opened a new position in Booz Allen Hamilton worth $75.6M.
- Adage Capital Partners's largest Q2 2022 buy was Booz Allen Hamilton: 837,064 shares worth $75.6M.
- Adage Capital Partners added most to Biohaven Pharmaceutical Holding Company Ltd. in Q2 2022, an estimated $364M increase.
- Adage Capital Partners's biggest Q2 2022 reduction was Royalty Pharma, cutting an estimated $333M.
- Adage Capital Partners fully exited Nutrien in Q2 2022, selling an estimated $213M.
- Adage Capital Partners's ten largest holdings make up 21% of its $43.6B portfolio in Q2 2022.
- Adage Capital Partners opened 110 new positions and closed 115 in Q2 2022.
- Adage Capital Partners's portfolio value fell 17% quarter-over-quarter to $43.6B.
Based on Adage Capital Partners's 13F filing for Q2 2022, filed 15 Aug 2022.